ERCC1

Summary

Gene Symbol: ERCC1
Description: ERCC excision repair 1, endonuclease non-catalytic subunit
Alias: COFS4, RAD10, UV20, DNA excision repair protein ERCC-1, excision repair cross-complementation group 1, excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence)
Species: human
Products:     ERCC1

Top Publications

  1. Lee H, Choi Y, Han J, Kim J, Jung J, Jeong S, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65:377-82 pubmed publisher
    ..stage IIIB with malignant pleural effusion or stage IV or recurrent disease were analyzed for p53, Bcl-2, Bax, and ERCC1 expression by immunohistochemistry...
  2. Fekairi S, Scaglione S, Chahwan C, Taylor E, Tissier A, Coulon S, et al. Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell. 2009;138:78-89 pubmed publisher
    ..Furthermore, we show that SLX4 binds the XPF(ERCC4) and MUS81 subunits of the XPF-ERCC1 and MUS81-EME1 endonucleases and is required for DNA interstrand crosslink repair...
  3. Jun H, Ahn M, Kim H, Yi S, Han J, Lee S, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008;99:167-72 pubmed publisher
    The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy...
  4. Sereno M, Cejas P, Moreno V, Belda Iniesta C, Lopez R, Nistal M, et al. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications. Int J Oncol. 2012;40:2104-10 pubmed publisher
    ..Excision repair cross complementation group 1 (ERCC1) is an enzyme that removes cisplatin-induced DNA adducts and has been related with prognosis and ..
  5. Vogel U, Sørensen M, Hansen R, Tjønneland A, Overvad K, Wallin H, et al. Gene-environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. Cancer Lett. 2007;247:159-65 pubmed
    Homozygous carriers of a haplotype consisting of ERCC1 Asn118Asn(A), ASE-1 G-21A(G), RAI IVS1 A4364G(A) are at increased risk of lung cancer especially among women...
  6. McKean Cowdin R, Barnholtz Sloan J, Inskip P, Ruder A, Butler M, Rajaraman P, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1118-26 pubmed publisher
    ..A significant, protective effect was found when three single-nucleotide polymorphisms (ERCC2 rs13181, ERCC1 rs3212986, and GLTSCR1 rs1035938) located near each other on chromosome 19 were modeled as a haplotype...
  7. Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, et al. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2013;72:315-22 pubmed publisher
    ..Five potentially functional polymorphisms (ERCC1 Asn118Asn, ERCC1 C8092A, XPD Lys751Gln, XRCC1 Arg399Gln and XRCC1 Arg280His) were genotyped using matrix-assisted ..
  8. Keam B, Im S, Han S, Ham H, Kim M, Oh D, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer. 2008;8:148 pubmed publisher
    ..The 6-bp deletion in TS-3'UTR might be a candidate to select patients who are likely to benefit from 5-FU based modified FOLFOX-6 in future large scale trial. ..
  9. Park S, Hong Y, Kim J, Kwak S, Cho J, Lee H, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol. 2006;23:489-98 pubmed
    A few reports for ERCC1 SNPs were conducted in patients treated with cisplatin chemotherapy...
  10. Chang P, Tzeng C, Chen P, Lin J, Lin T, Chen W, et al. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci. 2009;100:278-83 pubmed publisher
    We analyzed the influence of codon 118 C→T polymorphism of ERCC1 on its protein expression levels, clinicopathological features, and outcome of 168 Chinese patients with metastatic colorectal carcinoma that had been treated with first-..

Detail Information

Publications62

  1. Lee H, Choi Y, Han J, Kim J, Jung J, Jeong S, et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer. 2009;65:377-82 pubmed publisher
    ..stage IIIB with malignant pleural effusion or stage IV or recurrent disease were analyzed for p53, Bcl-2, Bax, and ERCC1 expression by immunohistochemistry...
  2. Fekairi S, Scaglione S, Chahwan C, Taylor E, Tissier A, Coulon S, et al. Human SLX4 is a Holliday junction resolvase subunit that binds multiple DNA repair/recombination endonucleases. Cell. 2009;138:78-89 pubmed publisher
    ..Furthermore, we show that SLX4 binds the XPF(ERCC4) and MUS81 subunits of the XPF-ERCC1 and MUS81-EME1 endonucleases and is required for DNA interstrand crosslink repair...
  3. Jun H, Ahn M, Kim H, Yi S, Han J, Lee S, et al. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008;99:167-72 pubmed publisher
    The excision repair cross-complementation group 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy...
  4. Sereno M, Cejas P, Moreno V, Belda Iniesta C, Lopez R, Nistal M, et al. ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implications. Int J Oncol. 2012;40:2104-10 pubmed publisher
    ..Excision repair cross complementation group 1 (ERCC1) is an enzyme that removes cisplatin-induced DNA adducts and has been related with prognosis and ..
  5. Vogel U, Sørensen M, Hansen R, Tjønneland A, Overvad K, Wallin H, et al. Gene-environment interactions between smoking and a haplotype of RAI, ASE-1 and ERCC1 polymorphisms among women in relation to risk of lung cancer in a population-based study. Cancer Lett. 2007;247:159-65 pubmed
    Homozygous carriers of a haplotype consisting of ERCC1 Asn118Asn(A), ASE-1 G-21A(G), RAI IVS1 A4364G(A) are at increased risk of lung cancer especially among women...
  6. McKean Cowdin R, Barnholtz Sloan J, Inskip P, Ruder A, Butler M, Rajaraman P, et al. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prev. 2009;18:1118-26 pubmed publisher
    ..A significant, protective effect was found when three single-nucleotide polymorphisms (ERCC2 rs13181, ERCC1 rs3212986, and GLTSCR1 rs1035938) located near each other on chromosome 19 were modeled as a haplotype...
  7. Chen C, Wang F, Wang Z, Li C, Luo H, Liang Y, et al. Polymorphisms in ERCC1 C8092A predict progression-free survival in metastatic/recurrent nasopharyngeal carcinoma treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol. 2013;72:315-22 pubmed publisher
    ..Five potentially functional polymorphisms (ERCC1 Asn118Asn, ERCC1 C8092A, XPD Lys751Gln, XRCC1 Arg399Gln and XRCC1 Arg280His) were genotyped using matrix-assisted ..
  8. Keam B, Im S, Han S, Ham H, Kim M, Oh D, et al. Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer. 2008;8:148 pubmed publisher
    ..The 6-bp deletion in TS-3'UTR might be a candidate to select patients who are likely to benefit from 5-FU based modified FOLFOX-6 in future large scale trial. ..
  9. Park S, Hong Y, Kim J, Kwak S, Cho J, Lee H, et al. Effect of ERCC1 polymorphisms and the modification by smoking on the survival of non-small cell lung cancer patients. Med Oncol. 2006;23:489-98 pubmed
    A few reports for ERCC1 SNPs were conducted in patients treated with cisplatin chemotherapy...
  10. Chang P, Tzeng C, Chen P, Lin J, Lin T, Chen W, et al. ERCC1 codon 118 C→T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci. 2009;100:278-83 pubmed publisher
    We analyzed the influence of codon 118 C→T polymorphism of ERCC1 on its protein expression levels, clinicopathological features, and outcome of 168 Chinese patients with metastatic colorectal carcinoma that had been treated with first-..
  11. Grimminger P, Shi M, Barrett C, Lebwohl D, Danenberg K, Brabender J, et al. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials. Pharmacogenomics J. 2012;12:404-11 pubmed publisher
    ..TS and ERCC-1 expression is associated with clinical outcome in mCRC. Baseline TS and ERCC-1 levels may allow the selection of patients who benefit from FOLFOX4 chemotherapy. ..
  12. Wei H, Lu X, Shang L, Xu G, Hu J, Che D, et al. Polymorphisms of ERCC1 C118T/C8092A and MDR1 C3435T predict outcome of platinum-based chemotherapies in advanced non-small cell lung cancer: a meta-analysis. Arch Med Res. 2011;42:412-20 pubmed publisher
    ..to compare outcome to platinum-based chemotherapies in advanced non-small cell lung cancer (NSCLC) with different ERCC1 C118T/C8092A and MDR1 C3435T polymorphisms...
  13. Carles J, Monzo M, Amat M, Jansa S, Artells R, Navarro A, et al. Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with Stage I to II head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2006;66:1022-30 pubmed
    ..Of the patients, 76 (70.4%) patients were Stage I and 32 (29.6%) were Stage II. The XPF/ERCC1 SNP at codon 259 and XPG/ERCC5 at codon 46 emerged as significant predictors of progression (p = 0.00005 and 0...
  14. Ruzzo A, Canestrari E, Maltese P, Pizzagalli F, Graziano F, Santini D, et al. Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. Clin Chem Lab Med. 2007;45:822-8 pubmed
    ..b>ERCC1 118 T/C, XRCC1 399 G/A, XPD 312 G/A, XPD 751 A/C, XRCC3 241 C/T, MS 919 A/G, GSTP1 105 A/G, GSTM1-null/positive ..
  15. Fisher L, Bessho M, Bessho T. Processing of a psoralen DNA interstrand cross-link by XPF-ERCC1 complex in vitro. J Biol Chem. 2008;283:1275-81 pubmed
    ..To investigate a role of the XPF-ERCC1 complex in this process, we designed a model substrate DNA with a single psoralen ICL at a three-way junction (Y-..
  16. Ota S, Ishii G, Goto K, Kubota K, Kim Y, Kojika M, et al. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer. 2009;64:98-104 pubmed publisher
    ....
  17. Scheil Bertram S, Tylus Schaaf P, du Bois A, Harter P, Oppitz M, Ewald Riegler N, et al. Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma. Gynecol Oncol. 2010;119:325-31 pubmed publisher
    The excision repair cross-complementation group 1 (ERCC1) expression is a predictor of survival after surgical treatment for several malignancies. Its overexpression has been reported as a marker of platinum resistance in lung cancer...
  18. Khrunin A, Moisseev A, Gorbunova V, Limborska S. Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J. 2010;10:54-61 pubmed publisher
    ..A higher risk of nephrotoxicity was noted for patients with the heterozygous ERCC1 19007 T/C and 8092 C/A genotypes. No correlations were found between genotypes and complete tumor responses.
  19. Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, et al. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis. Clin Cancer Res. 2008;14:2878-86 pubmed publisher
    The excision repair cross-complementation group 1 (ERCC1) plays a pivotal role in DNA repair and has been linked to protection against carcinogenesis and resistance to platinum-based anticancer drugs...
  20. Kang S, Ju W, Kim J, Park N, Song Y, Kim S, et al. Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med. 2006;38:320-4 pubmed
    b>ERCC1 is a DNA repair gene and has been associated with resistance to DNA damaging agents...
  21. Rageul J, Frémin C, Ezan F, Baffet G, Langouet S. The knock-down of ERCC1 but not of XPF causes multinucleation. DNA Repair (Amst). 2011;10:978-90 pubmed publisher
    Excision repair cross complementing gene 1 (ERCC1) associated with xeroderma pigmentosum group F (XPF) is a heterodimeric endonuclease historically involved in the excision of bulky helix-distorting DNA lesions during nucleotide excision ..
  22. Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clin Lung Cancer. 2009;10:118-23 pubmed publisher
    ..We retrospectively assessed whether single nucleotide polymorphisms (SNP) of DNA-repair genes ERCC1, XPD, XRCC1 and glutathione S-transferase genes GSTP1, GSTT1 and GSTM1 predict overall survival (OS), response and ..
  23. Ni M, Zhang W, Qiu J, Liu F, Li M, Zhang Y, et al. Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population. Sci Rep. 2014;4:4112 pubmed publisher
    The ERCC1 and ERCC2 genes are important in repairing DNA damage and genomic instability, and are involved in the nucleotide excision repair pathway...
  24. Chen D, Yao D, Zhao H, Yang S. DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis. Asian Pac J Cancer Prev. 2012;13:2791-4 pubmed
    We conducted a case-control study in a Chinese population to clarify the association between polymorphisms in ERCC1 and XPD and susceptibility and survival of glioma...
  25. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q. ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 2012;39:6933-42 pubmed publisher
    It is hypothesized that high expression of the excision repair cross-complementation group 1 (ERCC1) gene might be a positive prognostic factor, but predict decreased sensitivity to platinum-based chemotherapy...
  26. Li J, Ding Y, Li D, Peng R, Feng G, Zeng Y, et al. The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP. Cancer Biol Ther. 2009;8:1914-21 pubmed
    ....
  27. Vilmar A, Santoni Rugiu E, Sørensen J. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol. 2010;21:1817-24 pubmed publisher
    ..Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate...
  28. Yin M, Yan J, Voutsina A, Tibaldi C, Christiani D, Heist R, et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung Cancer. 2011;72:370-7 pubmed publisher
    ..The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage...
  29. Friboulet L, Barrios Gonzales D, Commo F, Olaussen K, Vagner S, Adam J, et al. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC. Clin Cancer Res. 2011;17:5562-72 pubmed publisher
    Excision repair cross-complementation group 1 (ERCC1) is a protein involved in repair of DNA platinum adducts and stalled DNA replication forks...
  30. Kudo K, Gavin E, Das S, Amable L, Shevde L, Reed E. Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair. Oncogene. 2012;31:4718-24 pubmed publisher
    The transcription of ERCC1 and other nucleotide excision repair (NER) genes is strongly influenced by c-jun. C-jun is transcriptionally regulated by Gli proteins of the Hedgehog pathway...
  31. Shen J, Desai M, Agrawal M, Kennedy D, Senie R, Santella R, et al. Polymorphisms in nucleotide excision repair genes and DNA repair capacity phenotype in sisters discordant for breast cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:1614-9 pubmed
    ..group C (XPC Lys939Gln and Ala499Val), group D (XPD Asp312Asn and Lys751Gln), and group G (XPG His1104Asp) and ERCC1 (8092 C>A) in a total of 160 sister pairs for whom DRC phenotype data were available...
  32. Bellmunt J, Paz Ares L, Cuello M, Cecere F, Albiol S, Guillem V, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol. 2007;18:522-8 pubmed
    ..Messenger RNA expression levels of excision repair cross complementing 1 (ERCC1), breast cancer 1 (BRCA1), ribonucleotide reductase subunit M1 (RRM1) and caveolin-1 were determined by RT-PCR in ..
  33. Kiyohara C, Yoshimasu K. Genetic polymorphisms in the nucleotide excision repair pathway and lung cancer risk: a meta-analysis. Int J Med Sci. 2007;4:59-71 pubmed
    ..pathway genes, focusing on xeroderma pigmentosum group A (XPA), excision repair cross complementing group 1 (ERCC1), ERCC2/XPD, ERCC4/XPF and ERCC5/XPG...
  34. Ma H, Xu L, Yuan J, Shao M, Hu Z, Wang F, et al. Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. Pharmacogenet Genomics. 2007;17:417-23 pubmed
    ..Excision repair cross-complementing group 1 (ERCC1) is one of the NER core enzymes, and polymorphisms in ERCC1 may lead to altered repair function of the enzyme and ..
  35. Yin J, Vogel U, Ma Y, Qi R, Wang H. Haplotypes of nine single nucleotide polymorphisms on chromosome 19q13.2-3 associated with susceptibility of lung cancer in a Chinese population. Mutat Res. 2008;641:12-8 pubmed publisher
    ..This result supports the hypothesis that the sub-region is important for lung cancer susceptibility. Haplotype studies using larger study groups will be required to obtain conclusive results. ..
  36. Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y, et al. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer. Lung Cancer. 2007;56:281-8 pubmed
    ..on chemotherapy and/or radiotherapy, we genotyped four single nucleotide polymorphisms (SNPs) in ATM (A60G), ERCC1 (Asn118Asn), APE1 (Asn148Glu), and iASPP (A67T), and examined their associations with treatment response among ..
  37. Jaspers N, Raams A, Silengo M, Wijgers N, Niedernhofer L, Robinson A, et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am J Hum Genet. 2007;80:457-66 pubmed
    ..The heterodimer ERCC1-XPF is one of two endonucleases required for NER...
  38. Ciccia A, Ling C, Coulthard R, Yan Z, Xue Y, Meetei A, et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell. 2007;25:331-43 pubmed
    ..Our data indicate that the FANCM/FAAP24 complex may play a key role in recruitment of the FA core complex to damaged DNA. ..
  39. Rubatt J, Darcy K, Tian C, Muggia F, Dhir R, Armstrong D, et al. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;125:421-6 pubmed publisher
    Excision repair cross-complementation group 1 (ERCC1) is required for the repair of platinum-induced DNA damage...
  40. Metzger R, Warnecke Eberz U, Alakus H, Kütting F, Brabender J, Vallbohmer D, et al. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis. J Gastrointest Surg. 2012;16:26-34; discussion 34 pubmed publisher
    ..To identify these patients, ERCC1 (rs11615) gene polymorphisms were analyzed...
  41. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan A, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14:1797-803 pubmed publisher
    ..Polymorphisms at the xeroderma pigmentosum group D (XPD), excision repair cross-complementing 1 (ERCC1), and cytidine deaminase (CDA) genes have been associated with alterations in enzymatic activity and may change ..
  42. Wei S, Zhan P, Shi M, Shi Y, Qian Q, Yu L, et al. Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis. Med Oncol. 2011;28:315-21 pubmed publisher
    The published data on the predictive value of polymorphism of ERCC1 and XPD in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy are inconclusive...
  43. Wu X, Lu C, Ye Y, Chang J, Yang H, Lin J, et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics. 2008;18:955-65 pubmed publisher
    ..Our results highlight the clinical potential of taking a pathway-based approach and using survival tree analytic approach to identify subgroups of patients with distinctly differing outcomes. ..
  44. Goekkurt E, Al Batran S, Hartmann J, Mogck U, Schuch G, Kramer M, et al. Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol. 2009;27:2863-73 pubmed publisher
    ..Polymorphisms within genes of TS, MTHFR, MTR, OPRT, XPD, ERCC1, XRCC1, XPA, GSTP1, GSTT1, and GSTM1 were genotyped using polymerase chain reaction-based techniques...
  45. Krivak T, Darcy K, Tian C, Armstrong D, Baysal B, Gallion H, et al. Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer. J Clin Oncol. 2008;26:3598-606 pubmed publisher
    We hypothesized that common polymorphisms in excision repair cross-complementation group 1 (ERCC1), involved in nucleotide excision repair of platinum-induced damage, would be associated with progression-free survival (PFS) and overall ..
  46. Warnecke Eberz U, Vallbohmer D, Alakus H, Kütting F, Lurje G, Bollschweiler E, et al. ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg. 2009;13:1411-21 pubmed publisher
    ..Single-nucleotide polymorphism ERCC1 C118T was predictive for therapy response (p < 0.003)...
  47. Hwang I, Ahn M, Park B, Ahn Y, Han J, Lee S, et al. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer. 2008;113:1379-86 pubmed publisher
    Excision repair cross-complementation Group 1 (ERCC1) overexpression is associated with resistance to cisplatin-based chemotherapy in patients with nonsmall-cell lung cancer (NSCLC)...
  48. Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer. 2008;62:105-12 pubmed publisher
    In this study, we examined the expression of excision repair cross-complementation group 1 (ERCC1) protein in 90 completely resected lung cancer samples from patients who received adjuvant or neo-adjuvant platinum-based chemotherapy...
  49. Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer. 2009;64:326-33 pubmed publisher
    ..The expression of excision repair cross-complementation group 1 (ERCC1) is reported to be correlated with resistance to platinum-based drugs...
  50. Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yukiue H, Yano M, et al. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer. J Surg Res. 2011;168:206-12 pubmed publisher
    It has been reported that the expression of excision repair cross-complementation group 1 (ERCC1) protein predicts the effect of platinum-based chemotherapy and overall survival in the several cancers...
  51. Kim S, Kwon H, Oh S, Lee D, Lee S, Lee J, et al. Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 2009;32:38-43 pubmed publisher
    The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced ..
  52. Leng X, Chen M, Xian L, Dai L, Ma G, Li M. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy. J Exp Clin Cancer Res. 2012;31:25 pubmed publisher
    The aim of this study was to investigate prognostic value of excision repair cross-complementing 1 (ERCC1), BCL2-associated athanogene (BAG-1), the breast and ovarian cancer susceptibility gene 1 (BRCA1), ribonucleotide reductase subunit ..
  53. Hubner R, Riley R, Billingham L, Popat S. Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations. PLoS ONE. 2011;6:e25164 pubmed publisher
    ..utility, several trials are already prospectively randomizing non-small cell lung cancer (NSCLC) patients by ERCC1 status...
  54. Ruzzo A, Graziano F, Loupakis F, Rulli E, Canestrari E, Santini D, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol. 2007;25:1247-54 pubmed
    ..reductase, xeroderma pigmentosum group D (XPD), excision repair cross complementing group 1 (ERCC1), x-ray cross complementing group 1, x-ray cross complementing protein 3, glutathione S-transferases (GSTs) genes...
  55. Köberle B, Brenner W, Albers A, Usanova S, ThUroff J, Kaina B. ERCC1 and XPF expression in human testicular germ cell tumors. Oncol Rep. 2010;23:223-7 pubmed
    ..In the present study we compared the expression of the NER proteins ERCC1 and XPF in 24 testicular germ cell tumors (TGCT) with the corresponding normal testicular tissue of the same ..
  56. Li Y, Gu S, Wu Q, Li Y, Fu X, Mao Y, et al. No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur J Hum Genet. 2007;15:967-73 pubmed
    ERCC1 (excision repair cross complementation group 1) is a subunit of the nucleotide excision repair complex, which can perform DNA strand incision correction of DNA damage...
  57. Tripsianes K, Folkers G, Zheng C, Das D, Grinstead J, Kaptein R, et al. Analysis of the XPA and ssDNA-binding surfaces on the central domain of human ERCC1 reveals evidence for subfunctionalization. Nucleic Acids Res. 2007;35:5789-98 pubmed
    Human ERCC1/XPF is a structure-specific endonuclease involved in multiple DNA repair pathways. We present the solution structure of the non-catalytic ERCC1 central domain...
  58. Lee K, Min H, Han S, Oh D, Lee S, Kim D, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 2008;60:401-7 pubmed
    Expression of excision repair cross-complementation group 1 (ERCC1) is important for resistance to platinum agents...
  59. Hansen R, Sørensen M, Tjønneland A, Overvad K, Wallin H, Raaschou Nielsen O, et al. A haplotype of polymorphisms in ASE-1, RAI and ERCC1 and the effects of tobacco smoking and alcohol consumption on risk of colorectal cancer: a Danish prospective case-cohort study. BMC Cancer. 2008;8:54 pubmed publisher
    ..The haplotype at chromosome 19q13.2-3 encompassing the three SNPs ASE-1 G-21A, RAI IVS1 A4364G and ERCC1 Asn118Asn have been associated with risk of breast cancer and lung cancer...
  60. Deng Q, Sheng L, Su D, Zhang L, Liu P, Lu K, et al. Genetic polymorphisms in ATM, ERCC1, APE1 and iASPP genes and lung cancer risk in a population of southeast China. Med Oncol. 2011;28:667-72 pubmed publisher
    ..We investigated the relationship between polymorphisms in ATM (A60G), ERCC1 (Asn118Asn), APE1 (Asn148Glu) and iASPP (A67T) and the risk of developing lung cancer...
  61. Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, et al. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer. Am J Clin Oncol. 2010;33:489-94 pubmed publisher
    ..this study was to investigate whether single nucleotide polymorphisms (SNPs) in polymorphisms of DNA repair gene ERCC1 (excision repair cross-complementation group 1) and XPD (ERCC2, excision repair cross-complementation group 2) ..
  62. Yin Z, Zhou B, He Q, Li M, Guan P, Li X, et al. Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. BMC Cancer. 2009;9:439 pubmed publisher
    Excision repair cross-complementing group 1 (ERCC1) and group 2 (ERCC2), and X-ray repair cross-complementing group 1 (XRCC1) proteins play important roles in the repair of DNA damage and adducts...